Repligen Corp to be acquired by Biolife

Repligen Corp enters into a merger agreement with Biolife Solutions, Inc. dated July 21, 2026, following the substitution of Bravo Merger Sub. Market relevance is high as the transaction significantly expands Biolife's portfolio in cell and tissue therapy.